GrowBLOX Sciences, Inc. (GBLX) Leverages Research
Post# of 118
Posted On: 09/15/2015 7:22:53 PM
GrowBLOX Sciences, Inc. (GBLX) Leverages Research Partner Discoveries to Fuel Growth
The state of Nevada is eager for its upcoming 2016 general election ballot initiative that proposes legalizing recreational use of marijuana. Using Colorado’s $700 million intake last year as a reference point, it sees the state trending to break $1 billion in annual revenues by 2016. With this data, projections from the state Department of Revenue tell us the MMJ market in Nevada could easily get a lot bigger in the months ahead.
GrowBLOX Sciences, Inc. focuses on the research and development of medical cannabis drugs and treatments. Producer of medical-grade cannabis, cannabis concentrates, and cannabinoid therapies through using various technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, the company is involved in the development of controlled-climate indoor agricultural technology growing and cultivation suites.
In the GBLX Drug Development Ecosystem, the company holds the patents and coordinates the research data from all of its research partners. Partner data is pulled together and partners are realize incentives with equity in relative to the value of the data they contribute. Bonus equity can be rewarded retroactively when data previously contributed becomes a part of a patent, IND filing, or NDA filing. The company finds that the equity incentive system increases efficiency and productivity in drug discovery. Further the company encourages real and virtual collaboration among the researchers in the ecosystem.
GB Sciences fills the discovery role in the ecosystem. Other members of the GBLX Drug Development Ecosystem include universities, small and medium biotechnology companies and clinical research organizations (CRO). Preclinical research comes by way of its University partners. Clinical trials are run by Clinical Research Organization (CRO) partners and can be licensed to Pharmaceutical Licensees before the Human Phase III trials. Distribution is through specialty pharmaceutical channels, including hospitals and research centers.
GrowBLOX Sciences combines state-of-the-art technologies in plant biology, cultivation and post-production processes to optimize safe medical Cannabis. The company is pioneering technologies and industry-leading processes in combination with a Big Data-driven clinical research and development program to bring relief to patients all over the United States.
To learn more about the company visit www.growblox.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
The state of Nevada is eager for its upcoming 2016 general election ballot initiative that proposes legalizing recreational use of marijuana. Using Colorado’s $700 million intake last year as a reference point, it sees the state trending to break $1 billion in annual revenues by 2016. With this data, projections from the state Department of Revenue tell us the MMJ market in Nevada could easily get a lot bigger in the months ahead.
GrowBLOX Sciences, Inc. focuses on the research and development of medical cannabis drugs and treatments. Producer of medical-grade cannabis, cannabis concentrates, and cannabinoid therapies through using various technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, the company is involved in the development of controlled-climate indoor agricultural technology growing and cultivation suites.
In the GBLX Drug Development Ecosystem, the company holds the patents and coordinates the research data from all of its research partners. Partner data is pulled together and partners are realize incentives with equity in relative to the value of the data they contribute. Bonus equity can be rewarded retroactively when data previously contributed becomes a part of a patent, IND filing, or NDA filing. The company finds that the equity incentive system increases efficiency and productivity in drug discovery. Further the company encourages real and virtual collaboration among the researchers in the ecosystem.
GB Sciences fills the discovery role in the ecosystem. Other members of the GBLX Drug Development Ecosystem include universities, small and medium biotechnology companies and clinical research organizations (CRO). Preclinical research comes by way of its University partners. Clinical trials are run by Clinical Research Organization (CRO) partners and can be licensed to Pharmaceutical Licensees before the Human Phase III trials. Distribution is through specialty pharmaceutical channels, including hospitals and research centers.
GrowBLOX Sciences combines state-of-the-art technologies in plant biology, cultivation and post-production processes to optimize safe medical Cannabis. The company is pioneering technologies and industry-leading processes in combination with a Big Data-driven clinical research and development program to bring relief to patients all over the United States.
To learn more about the company visit www.growblox.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)